Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 13/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 12/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL772361 | 0.99 | PRKCA (0.47) | PRKCAMMP12SCN9ANR1I2CYP3A4 | |
| SCHEMBL772808 | 0.92 | PRKCA (0.50) | PRKCAMMP12SCN9ANR1I2CYP3A4 | |
| SCHEMBL772843 | 0.92 | PRKCA (0.49) | PRKCAMMP12SCN9ANR1I2CYP3A4 | |
| SCHEMBL773986 | 0.92 | PRKCA (0.49) | PRKCAMMP12SCN9ANR1I2CYP3A4 | |
| SCHEMBL774051 | 0.92 | PRKCA (0.49) | PRKCAMMP12SCN9ANR1I2CYP3A4 | |
| SCHEMBL12429032 | 0.91 | PRKCA (0.47) | PRKCAMMP12SCN9ANR1I2CYP3A4 | |
| Hydrochloric Acid SCHEMBL773029 | 0.91 | PRKCA (0.47) | PRKCAMMP12SCN9ANR1I2CYP3A4 | |
| SCHEMBL771797 | 0.90 | PRKCA (0.49) | PRKCAMMP12SCN9ANR1I2CYP3A4 | |
| SCHEMBL771119 | 0.89 | PRKCA (0.48) | PRKCAMMP12SCN9ANR1I2CYP3A4 | |
| SCHEMBL773010 | 0.89 | PRKCA (0.49) | PRKCAMMP12SCN9ANR1I2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | PRKCA 2404/4885MMP12 1013/4885SCN9A 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.